Literature DB >> 9136240

An analysis of children with typhoid fever admitted in 1991.

C T Deshmukh1, U B Nadkarni, S C Karande.   

Abstract

In 28 children, with bacteriologically and/or serologically diagnosed typhoid fever treated at KEM Hospital, Bombay in 1991, initially one of the three recommended drugs (viz. chloramphenicol, amoxycillin or co-trimoxazole) was given for 7 days for defervescence to occur. In those who failed to respond, a second trial of therapy with one of the other two drugs was initiated, after omitting the first drug. A second failure of therapy was taken as an indication to use ciprofloxacin singly. Eventually, 18 (64.3%) cases responded to chloramphenicol or amoxycillin or co-trimoxazole. Ciprofloxacin was used in 19(35.7%) cases. the failure rate of treatment with chloramphenicol was 50%, with amoxycillin 71.4%, with co-trimoxazole 75% and 0% with ciprofloxacin. An analysis of the 28 cases revealed that apart from fever (in 100%), splenomegaly (in 82.1%) was the most important clinical pointer to diagnosis, along with absolute eosinopenia (in 71.4%). There were no major complications, except 2 cases with typhoid hepatitis who responded to choramphenicol and co-trimoxazole, respectively. Blood culture grew Salmonella typhi in 7 cases, of which 5 (72%) were multidrug resistant S. typhi. There were no characteristic clinical features to identify multi-drug resistant typhoid fever.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9136240

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  3 in total

1.  Baseline Widal titres in healthy children.

Authors:  Anand M Patil; M L Kulkarni; Akhil M Kulkarni
Journal:  Indian J Pediatr       Date:  2007-12       Impact factor: 1.967

2.  Profile of typhoid fever in children from a tertiary care hospital in Chennai-South India.

Authors:  Ramaswamy Ganesh; Lalitha Janakiraman; Thiruvengadam Vasanthi; Malathi Sathiyasekeran
Journal:  Indian J Pediatr       Date:  2010-09-30       Impact factor: 1.967

3.  Reply to Farmakiotis et al.

Authors:  Claire S Waddington; Thomas C Darton; Brian Angus; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2014-07-30       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.